Rheumatoid arthritis and ankylosing spondylitis - Pathology of acute inflammation

Clinical and Experimental Rheumatology

Volumn 27, Issue 4 SUPPL. 55, 2009, Pages

  Appel, Heiner ^a   Loddenkemper, Christoph ^a   Miossec, Pierre ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

Ankylosing spondylitis; Immunopathology; Rheumatoid arthritis

Indexed keywords

ABATACEPT; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 17; INTERLEUKIN 6; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; ANTIGEN PRESENTING CELL; BONE DESTRUCTION; BONE MARROW; CELL DENSITY; CORTICAL BONE; EDEMA; EFFECTOR CELL; HISTOLOGY; HUMAN; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MICROVASCULATURE; MORPHOLOGY; MYELITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEITIS; OSTEOCLAST; OUTCOME ASSESSMENT; PATHOLOGY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SACROILIAC JOINT; SYNOVIUM; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ACUTE DISEASE; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE MARROW; CYTOKINES; HUMANS; OSTEITIS; OSTEOGENESIS; SACROILIAC JOINT; SPONDYLITIS, ANKYLOSING; SYNOVIAL MEMBRANE; T-LYMPHOCYTES, REGULATORY;

EID: 71249104263     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. KLARESKOG L, CATRINA AI et al.: Rheumatoid arthritis. Lancet 2009; 373: 659-672
2. AUGER I, SEBBAG M et al. Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen. Arthritis Rheum 2005; 52: 3424-3432
3. FIRESTEIN GS: Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-361
4. SIEPER J, RUDWALEIT M, KHAN MA, BRAUN J: Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol 2006; 20: 401-417
5. HERMANN KG, ALTHOFF CE, SCHNEIDER U et al. Spinal changes in patients with spondylarthritis: comparison of MR imaging and radiographic appearances. Radiographics 2005; 25: 559-569 (Pubitemid 40826776)
6. VAN DER LINDEN SM, VALKENBURG HA, DE JONGH BM, CATS A: The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984; 27: 241-249
7. SCHETT G: Immune cells and mediators of inflammatory arthritis. Autoimmunity 2008; 41: 224-229
8. BRENNAN FM and MCINNES IB: Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118: 3537-3545
9. MIOSSEC P: Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum 2007; 56: 2111-2115
10. MCINNES, IB and SCHETT G: Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429-442
11. APPEL H, KUHNE M, SPIEKERMANN S et al. Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum 2006; 54: 1805-1813
12. SCHETT G: Bone marrow edema. Ann N Y Acad Sci 2009; 1154: 35-40.
13. POOLE AR: The histopathology of ankylosing spondylitis: are there unifying hypotheses? Am J Med Sci 1998; 316: 228-233
14. MCGONAGLE D, GIBBON W, EMERY P: Classification of inflammatory arthritis by enthesitis. Lancet 1998; 352: 1137-1140
15. MAKSYMOWYCH WP: Ankylosing spondylitis - at the interface of bone and cartilage. J Rheumatol 2000; 27: 2295-2301
16. CRUICKSHANK B: Lesions of cartilaginous joints in ankylosing spondylitis. J Pathol Bacteriol 1956; 71: 73-84.
17. BYWATERS EGL, OLSEN E: A case of early ankylosing spondylitis with fatal secondary amyloidosis: demonstrated at the Royal Postgraduate Medical School. BMJ 1968; 2: 412-416.
18. FRANCOIS RJ, GARDNER DL, DEGRAVE EJ, BYWATERS EG: Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum 2000; 43: 2011-2024
19. BRAUN J, BOLLOW M, NEURE L et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505.
20. SAVILL DL: The manubrio-sternal joint in ankylosing spondylitis. J Bone Joint Surg Br 1951; 33: 56-64.
21. JIMENEZ-BOJ E, NÖBAUER-HUHMANN I, HANSLIK-SCHNABEL B et al. Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum 2007; 56: 1118-1124
22. LALOUX L, VOISIN MC, ALLAIN J et al.: Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001; 60: 316-321
23. BRAUN J, BOLLOW M, EGGENS U, KÖNIG H, DISTLER A, SIEPER J: Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994; 37: 1039-1045
24. BOLLOW M, FISCHER T, REISSHAUER H et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000; 59: 135-140
25. GOLDER W, KARBERG K, SIEPER J: Fluoroscopy-guided application of corticosteroids for local control of manubriosternal joint pain in patients with spondyloarthropathies. Clin Rheumatol 2004; 23: 481-484
26. MCGONAGLE D, GIBBON W, O'CONNOR P, GREEN M, PEASE C, EMERY P: Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum 1998: 41: 694-700.
27. LAMBERT RG, DHILLON SS, JHANGRI GS et al.: High prevalence of symptomatic enthesopathy of the shoulder in ankylosing spondylitis: deltoid origin involvement constitutes a hallmark of disease. Arthritis Rheum 2004; 51: 681-690
28. MIOSSEC P: Dynamic interactions between T cells and dendritic cells and their derived cytokines/chemokines in the rheumatoid synovium. Arthritis Res Ther 2008; 10 (Suppl. 1): S2.
29. HARINGMAN JJ, OOSTENDORP RL et al.: Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis. Expert Opin Emerg Drugs 2005; 10: 299-310.
30. PAGE G, MIOSSEC P: Paired synovium and lymph nodes from rheumatoid arthritis patients differ in dendritic cell and chemokine expression. J Pathol 2004 ; 204: 28-38.
31. PAGE G, LEBECQUE S et al.: Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium. J Immunol 2002 : 168: 5333-5341
32. MOSER K, TOKOYODA K et al.: Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol 2006; 18: 265-270
33. APPEL H, KUHNE M, SPIEKERMANN S et al.: Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006; 54: 2845-51.
34. APPEL H, LODDENKEMPER C, GROZDANOVIC Z et al.: Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther 2006; 8: R143.
35. MAINI R, ST CLAIR EW et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-1939.
36. VAN LENT P L, VAN DE LOO FA et al.: Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J Rheumatol 1995; 22: 2250-2258
37. NISHIMOTO N, YOSHIZAKI K et al.: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 1761-1769
38. BRANDT J, HAIBEL H, CORNELY D et al.: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346-1352
39. BRAUN J, SIEPER J: Ankylosing spondylitis. Lancet 2007; 369: 1379-1390
40. APPEL H, HEYDRICH R, LODDENKEMPER C, HEMPFING A, SIEPER J: In situ detection of IL-17 secreting cells in the bone marrow of facet joints obtained from patients with ankylosing spondylitis. Arthritis Rheum 2008; 58 (Suppl.): S946.
41. EHRENSTEIN MR, EVANS JG et al.: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200: 277-285
42. BETTELLI E, CARRIER Y et al.: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238
43. + T cells in patients with Anklyosing Spondylitis and other inflammatory joint diseases. Arthritis Rheum 2008; 58 (Suppl.): S946.
44. CHABAUD M, FOSSIEZ F et al.: Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998; 161: 409-414
45. RUDWALEIT M, LISTING J, BRANDT J, BRAUN J, SIEPER J: Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 665-70.
46. HAIBEL H, RUDWALEIT M, LISTING J et al.: Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008; 58: 1981-1991
47. SONG IH, HELDMANN F, RUDWALEIT M et al.: Major clinical response of Rituximab in active TNF-blocker naïve patients with ankylosing spondylitis but not in TNF-blocker failure patients: an open label clinical trial. Ann Rheum Dis 2009; EULAR OP-0021.